This system defines about 50 genomic tests with sufficient evidence for clinical implementation (e.g., KRAS and human epidermal growth factor receptor 2 (HER2) tests to inform use of cetuximab in colorectal cancer and lapatinib in breast cancer, respectively). This evidence concerns the gene ERBB2 and breast cancer.